Celularity Inc.

CELU

US1511902041

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-28 EDT			5-day change	1st Jan Change
3.37 ^USD	-2.60%		+11.59%	+36.22%

05-21	Transcript : Celularity Inc. - Analyst/Investor Day
03-26	Celularity Receives Healthcare Common Procedure Coding System Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L	CI

Celularity Inc. Announces Resignation of Andrew L. Pecora, M.D., F.A.C.P., as Company’s President Effective as of August 31, 2022

September 23, 2022 at 04:06 pm

Celularity Inc, announced on July 20, 2022, Andrew L. Pecora, M.D., F.A.C.P., resigned as Celularity's President effective as of August 31, 2022.

Latest news about Celularity Inc.

Transcript : Celularity Inc. - Analyst/Investor Day	05-21
Celularity Receives Healthcare Common Procedure Coding System Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L	03-26	CI
Celularity Seeks FDA Orphan Drug Status for PDA-002 in Facioscapulohumeral Muscular Dystrophy	03-20	MT
Celularity Inc. announced that it expects to receive $10 million in funding from Yorkville Advisors Global LP	03-12	CI
Celularity to Execute Reverse Stock Split Next Week	02-23	MT
Celularity Inc. Provides Sales Guidance for the First Quarter and Full Year 2024	02-01	CI
Celularity Insider Bought Shares Worth $5,331,335, According to a Recent SEC Filing	01-17	MT
Genting Berhad Engages in Discussions with Celularity Inc	01-17	CI
Celularity Inc. announced that it has received $6 million in funding from Dragasac Limited	01-15	CI
Celularity Inc. announced that it expects to receive $6 million in funding from Dragasac Limited	01-11	CI
Celularity, BioCellgraft Strike Deal for Placental-Derived Biomaterial Products	01-04	MT
Celularity Inc. Confirms Commercialization Agreement with BioCellgraft, Inc. for Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare	01-04	CI
Celularity Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023	01-03	CI
North American Morning Briefing : Stock Futures Extend Losses as FOMC Minutes Awaited	01-03	DJ
Celularity Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	01-03	CI
Celularity Inc. Announces Resignation of Robin L. Smith, MD, from Board of Directors	12-29	CI
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight	12-20	DJ
North American Morning Briefing : Traders Await FOMC, Powell	12-13	DJ
North American Morning Briefing : Stock Futures Rise With More Jobs Data on Tap	12-06	DJ
Celularity Receives Non-Compliance Notice From Nasdaq	11-24	MT
North American Morning Briefing : Stock Futures Muted; Nvidia Slips in Offhours Trading	11-22	DJ
Lim Kok Thay Notifies Celularity Inc. of His Intention to Resign as a Member of the Board and All Committees	23-09-19	CI
Celularity Inc.(NasdaqCM:CELU) dropped from S&P Global BMI Index	23-09-18	CI
Celularity Inc. Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors	23-09-07	CI
Celularity to Support Research of Regeneron's Allogeneic Cell Therapy Candidates for Solid Tumors	23-08-29	MT

Celularity Inc. is a clinical-stage biotechnology company. The Company is engaged in developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen receptor (CAR), natural killer, cells, mesenchymal-like adherent stromal cells (MLASCs), and exosomes. These therapeutic candidates target indications across cancer, infectious and degenerative diseases. Its cell therapeutic programs include CYCART-19, CYCART-201, CYNK-001, CYNK-301, CYNK-302, APPL-001, and pEXO-001. CYCART-19 is a placental-derived CAR-T cell therapy, in development for the treatment of B-cell malignancies, initially targeting the cluster of differentiation 19. pExo-001 is developed for the treatment of osteoarthritis. APPL-001 is developed for the treatment of Crohnâs disease.

Sector

Biotechnology & Medical Research

Calendar

2024-05-29 - Orthopedic Research Society Tendon Conference

More about the company

	1st Jan change	Capi.
CELULARITY INC.	+36.22%	73.41M
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	115B
REGENERON PHARMACEUTICALS, INC.	+10.80%	105B
BIONTECH SE	-10.84%	22.71B
ARGENX SE	-1.51%	21.83B
GENMAB A/S	-11.02%	18.18B
WUXI APPTEC CO., LTD.	-41.92%	16.52B
BEIGENE, LTD.	-15.11%	16.01B
NEUROCRINE BIOSCIENCES, INC.	+6.62%	14.14B
SAREPTA THERAPEUTICS, INC.	+17.53%	10.71B

Bio Therapeutic Drugs

Celularity Inc.

Equities

CELU

US1511902041

Biotechnology & Medical Research

Celularity Inc. Announces Resignation of Andrew L. Pecora, M.D., F.A.C.P., as Company’s President Effective as of August 31, 2022

Latest news about Celularity Inc.

Chart Celularity Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs